Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma
The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2015-01, Vol.29 (1), p.133-136 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 136 |
|---|---|
| container_issue | 1 |
| container_start_page | 133 |
| container_title | In vivo (Athens) |
| container_volume | 29 |
| creator | Carleo, Maria Aurora Di Martino, Filomena Del Giudice, Annalisa Gargiulo, Miriam Parrella, Giovanni Rosario, Pietro Sangiovanni, Vincenzo Viglietti, Rosaria Esposito, Vincenzo Chirianni, Antonio |
| description | The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS.
We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r).
Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661328900</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661328900</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-d2965367093036233ef279f393a6629ab80b069f59faf1e773542159045054ef3</originalsourceid><addsrcrecordid>eNo1kMtOwzAURCMkREvhF5CXbCL5UTv1EpVHKyqxAbbRTXJdjGI72G4Rf48RsJrN6OjMnFRz1mhWN3KpZ9V5Su-UqoZSflbNuFSUyiWfV5-31hiM6DOxboI-k2AI-GzriDmGo40wkoh769CTPvgM1lu_J1MMGSEhsf7NdjaHmEjwZMAjjmFyP7wC2mxfC2eEjAN5hCkkSxLEPji4qE4NjAkv_3JRvdzfPa839e7pYbu-2dUTZyzXA9dKiqKtBRWKC4GGN9oILUAprqFb0Y4qbaQ2YBg2jSirmNR0Kcs-NGJRXf9yi_DHAVNunU09jiN4DIfUMqWY4CtNaale_VUPncOhnaJ1EL_a_7PEN1yWZVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661328900</pqid></control><display><type>article</type><title>Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Carleo, Maria Aurora ; Di Martino, Filomena ; Del Giudice, Annalisa ; Gargiulo, Miriam ; Parrella, Giovanni ; Rosario, Pietro ; Sangiovanni, Vincenzo ; Viglietti, Rosaria ; Esposito, Vincenzo ; Chirianni, Antonio</creator><creatorcontrib>Carleo, Maria Aurora ; Di Martino, Filomena ; Del Giudice, Annalisa ; Gargiulo, Miriam ; Parrella, Giovanni ; Rosario, Pietro ; Sangiovanni, Vincenzo ; Viglietti, Rosaria ; Esposito, Vincenzo ; Chirianni, Antonio</creatorcontrib><description>The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS.
We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r).
Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients.</description><identifier>EISSN: 1791-7549</identifier><identifier>PMID: 25600542</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; CD4 Lymphocyte Count ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV Protease Inhibitors - pharmacology ; HIV Protease Inhibitors - therapeutic use ; Humans ; Male ; Middle Aged ; Risk Factors ; Sarcoma, Kaposi - drug therapy ; Sarcoma, Kaposi - etiology ; Sarcoma, Kaposi - pathology ; Sarcoma, Kaposi - prevention & control ; Treatment Outcome ; Viral Load ; Young Adult</subject><ispartof>In vivo (Athens), 2015-01, Vol.29 (1), p.133-136</ispartof><rights>Copyright © 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25600542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carleo, Maria Aurora</creatorcontrib><creatorcontrib>Di Martino, Filomena</creatorcontrib><creatorcontrib>Del Giudice, Annalisa</creatorcontrib><creatorcontrib>Gargiulo, Miriam</creatorcontrib><creatorcontrib>Parrella, Giovanni</creatorcontrib><creatorcontrib>Rosario, Pietro</creatorcontrib><creatorcontrib>Sangiovanni, Vincenzo</creatorcontrib><creatorcontrib>Viglietti, Rosaria</creatorcontrib><creatorcontrib>Esposito, Vincenzo</creatorcontrib><creatorcontrib>Chirianni, Antonio</creatorcontrib><title>Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS.
We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r).
Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients.</description><subject>Adult</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>CD4 Lymphocyte Count</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Risk Factors</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Sarcoma, Kaposi - etiology</subject><subject>Sarcoma, Kaposi - pathology</subject><subject>Sarcoma, Kaposi - prevention & control</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURCMkREvhF5CXbCL5UTv1EpVHKyqxAbbRTXJdjGI72G4Rf48RsJrN6OjMnFRz1mhWN3KpZ9V5Su-UqoZSflbNuFSUyiWfV5-31hiM6DOxboI-k2AI-GzriDmGo40wkoh769CTPvgM1lu_J1MMGSEhsf7NdjaHmEjwZMAjjmFyP7wC2mxfC2eEjAN5hCkkSxLEPji4qE4NjAkv_3JRvdzfPa839e7pYbu-2dUTZyzXA9dKiqKtBRWKC4GGN9oILUAprqFb0Y4qbaQ2YBg2jSirmNR0Kcs-NGJRXf9yi_DHAVNunU09jiN4DIfUMqWY4CtNaale_VUPncOhnaJ1EL_a_7PEN1yWZVs</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Carleo, Maria Aurora</creator><creator>Di Martino, Filomena</creator><creator>Del Giudice, Annalisa</creator><creator>Gargiulo, Miriam</creator><creator>Parrella, Giovanni</creator><creator>Rosario, Pietro</creator><creator>Sangiovanni, Vincenzo</creator><creator>Viglietti, Rosaria</creator><creator>Esposito, Vincenzo</creator><creator>Chirianni, Antonio</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma</title><author>Carleo, Maria Aurora ; Di Martino, Filomena ; Del Giudice, Annalisa ; Gargiulo, Miriam ; Parrella, Giovanni ; Rosario, Pietro ; Sangiovanni, Vincenzo ; Viglietti, Rosaria ; Esposito, Vincenzo ; Chirianni, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-d2965367093036233ef279f393a6629ab80b069f59faf1e773542159045054ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>CD4 Lymphocyte Count</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Risk Factors</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Sarcoma, Kaposi - etiology</topic><topic>Sarcoma, Kaposi - pathology</topic><topic>Sarcoma, Kaposi - prevention & control</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carleo, Maria Aurora</creatorcontrib><creatorcontrib>Di Martino, Filomena</creatorcontrib><creatorcontrib>Del Giudice, Annalisa</creatorcontrib><creatorcontrib>Gargiulo, Miriam</creatorcontrib><creatorcontrib>Parrella, Giovanni</creatorcontrib><creatorcontrib>Rosario, Pietro</creatorcontrib><creatorcontrib>Sangiovanni, Vincenzo</creatorcontrib><creatorcontrib>Viglietti, Rosaria</creatorcontrib><creatorcontrib>Esposito, Vincenzo</creatorcontrib><creatorcontrib>Chirianni, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carleo, Maria Aurora</au><au>Di Martino, Filomena</au><au>Del Giudice, Annalisa</au><au>Gargiulo, Miriam</au><au>Parrella, Giovanni</au><au>Rosario, Pietro</au><au>Sangiovanni, Vincenzo</au><au>Viglietti, Rosaria</au><au>Esposito, Vincenzo</au><au>Chirianni, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2015-01</date><risdate>2015</risdate><volume>29</volume><issue>1</issue><spage>133</spage><epage>136</epage><pages>133-136</pages><eissn>1791-7549</eissn><abstract>The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS.
We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r).
Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients.</abstract><cop>Greece</cop><pmid>25600542</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7549 |
| ispartof | In vivo (Athens), 2015-01, Vol.29 (1), p.133-136 |
| issn | 1791-7549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1661328900 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology HIV Protease Inhibitors - pharmacology HIV Protease Inhibitors - therapeutic use Humans Male Middle Aged Risk Factors Sarcoma, Kaposi - drug therapy Sarcoma, Kaposi - etiology Sarcoma, Kaposi - pathology Sarcoma, Kaposi - prevention & control Treatment Outcome Viral Load Young Adult |
| title | Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A58%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20impact%20of%20anti-retroviral%20regimen%20containing%20protease%20inhibitors%20on%20development%20of%20HIV-related%20Kaposi%20sarcoma&rft.jtitle=In%20vivo%20(Athens)&rft.au=Carleo,%20Maria%20Aurora&rft.date=2015-01&rft.volume=29&rft.issue=1&rft.spage=133&rft.epage=136&rft.pages=133-136&rft.eissn=1791-7549&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1661328900%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661328900&rft_id=info:pmid/25600542&rfr_iscdi=true |